Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease
- PMID: 19180517
- DOI: 10.1002/art.24267
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease
Abstract
Objective: Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be isolated (pulmonary arterial hypertension [PAH]) or associated with interstitial lung disease (ILD). This study was undertaken to characterize determinants of survival among SSc patients with either type of PH who received PAH-specific therapy.
Methods: Consecutive SSc patients with PAH or ILD-associated PH confirmed by right heart catheterization were included in the study. Kaplan-Meier and Cox proportional hazards models were used to compare survival between SSc patients with PAH and those with ILD-associated PH and to identify predictors of survival.
Results: Fifty-nine patients (39 with PAH and 20 with ILD-associated PH) were identified. The majority (15 of 20 with ILD-associated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy. Median followup time was 4.4 years (range 2.7-7.4 years). Survival was significantly worse in SSc patients with ILD-associated PH than in those with PAH (1-, 2-, and 3-year survival rates 82%, 46%, and 39% versus 87%, 79%, and 64%, respectively; P < 0.01 by log rank test). In a multivariable analysis, ILD-associated PH was associated with a 5-fold increase in risk of death compared with PAH. Pulmonary vascular resistance index was also an independent predictor of mortality in the overall cohort (hazard ratio 1.05, P < 0.01) and was a significant univariable risk factor in each group separately. Type of initial PAH therapy and the use of warfarin were not related to survival.
Conclusion: Survival in SSc complicated by PH remains poor despite currently available treatment options. While therapy may be associated with improved survival in PAH compared with historical controls, the prognosis for patients with ILD-associated PH is particularly grim. Early diagnosis and treatment may improve outcomes since worsening hemodynamic factors were associated with reduced survival.
Similar articles
-
Improved transplant-free survival in patients with systemic sclerosis-associated pulmonary hypertension and interstitial lung disease.Arthritis Rheumatol. 2014 Jul;66(7):1900-8. doi: 10.1002/art.38623. Arthritis Rheumatol. 2014. PMID: 24729406
-
Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease.Chest. 2011 Oct;140(4):1016-1024. doi: 10.1378/chest.10-2473. Epub 2011 Apr 7. Chest. 2011. PMID: 21474572
-
Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease.Arthritis Rheumatol. 2021 Feb;73(2):295-304. doi: 10.1002/art.41512. Epub 2020 Dec 29. Arthritis Rheumatol. 2021. PMID: 32892515
-
Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31. doi: 10.1093/rheumatology/kep107. Rheumatology (Oxford). 2009. PMID: 19487219 Review.
-
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.Drugs. 2008;68(12):1635-45. doi: 10.2165/00003495-200868120-00003. Drugs. 2008. PMID: 18681488 Review.
Cited by
-
Clinical Characteristics of Systemic Sclerosis With Interstitial Lung Disease.Arch Rheumatol. 2018 Jan 15;33(3):322-327. doi: 10.5606/ArchRheumatol.2018.6630. eCollection 2018 Sep. Arch Rheumatol. 2018. PMID: 30632529 Free PMC article.
-
A contemporary update on scleroderma.Clin Rev Allergy Immunol. 2011 Apr;40(2):75-7. doi: 10.1007/s12016-010-8200-8. Clin Rev Allergy Immunol. 2011. PMID: 20300968 No abstract available.
-
Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension.Pulm Circ. 2019 Jul 29;9(3):2045894019859477. doi: 10.1177/2045894019859477. eCollection 2019 Jul-Sep. Pulm Circ. 2019. PMID: 31384431 Free PMC article.
-
Characterization of connective tissue disease-associated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype.Chest. 2010 Dec;138(6):1383-94. doi: 10.1378/chest.10-0260. Epub 2010 May 27. Chest. 2010. PMID: 20507945 Free PMC article.
-
Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.Arthritis Rheumatol. 2019 Aug;71(8):1339-1349. doi: 10.1002/art.40862. Epub 2019 Jun 18. Arthritis Rheumatol. 2019. PMID: 30762947 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical